Imaradenant (AZD4635)
规格
| Cas Number | 1321514-06-0 |
| 规格或纯度 | Moligand™, ≥98% |
| 级别 | Moligand™ |
| 纯度 | ≥98% |
| 包装 | 100mg 或 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| Action Type | 拮抗剂 |
| Mechanism Of Action | 腺苷 A2a 受体拮抗剂 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 63 mg/mL (199.53 mM); Ethanol: 4 mg/mL (12.66 mM); Water: Insoluble; |
| 简短描述 | 腺苷受体拮抗剂 |
| 英文简短描述 | Adenosine Receptor Antagonists |
| 过滤标签 | A1 receptor Antagonist,A2A receptor Antagonist,A2B receptor Antagonist,Adenosine Receptor,GPCR/G Protein |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | Imaradenant（AZD4635，HTL1071）是一种口服 A2AR 拮抗剂，它与人类 A2AR 的 Ki 值为 1.7 nM，选择性超过其他腺苷受体的 30 倍。 |
| 描述 |
产品介绍 |
| 英文描述 |
Information Imaradenant (AZD4635) Imaradenant (AZD4635, HTL1071) is an oral A2AR antagonist that binds to human A2AR with a Ki of 1.7 nM and with > 30-fold selectivity over other adenosine receptors. Targets A2AR (Cell-free) 1.7 nM(Ki) In vitro In CHO cells stably expressing human A2AR, the IC50s of AZD4635 for inhibition of cAMP production are 0.79, 10.0 and 142.9 nM in the presense of 0.1, 1 and 10 μM adenosine, respectively. In vivo Blockade of A2AR signaling with AZD4635 could reduce tumor burden and enhance antitumor immunity. |